GRPR overexpression has been documented in 63–100% of primary prostate cancer samples and in the majority of lymph node and bone metastases, while most benign and hyperplastic prostate cells are GRPR negative [12,13,14,15]. This evidence concerns the gene GRPR and prostate carcinoma.